



FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS

TOTAL COMPANY

WORLDWIDE SALES

FULL YEAR

GROWTH ON AN
ORGANIC BASIS*

FOURTH QUARTER

\$43.7B **+6.4%¹**

\$10.1B

ADJUSTED DILUTED EPS

FULL YEAR

FOURTH QUARTER

\$5.34²

\$1.03³

**EXCEEDED FULL-YEAR
GUIDANCE ISSUED IN JANUARY 2022**

AT LEAST \$4.70⁴ ADJUSTED DILUTED EPS

FULL-YEAR 2022: BUSINESS UNIT SALES



\$14.7B
MEDICAL DEVICES



\$16.6B
DIAGNOSTICS



\$7.5B
NUTRITION



\$4.9B
ESTABLISHED
PHARMACEUTICALS

FULL-YEAR 2023 GUIDANCE

\$4.30 to \$4.50⁵ ADJUSTED DILUTED EPS

BUSINESS HIGHLIGHTS

NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) SYSTEM

- ▶ FDA approval adds to Abbott's comprehensive transcatheter structural heart portfolio
- ▶ Offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease



FREESTYLE LIBRE®** NAMED "BEST MEDICAL TECHNOLOGY" IN THE LAST 50 YEARS

BY THE GALIEN
FOUNDATION



ETERNA™ SPINAL CORD STIMULATION SYSTEM

- ▶ FDA approval of the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain⁶
- ▶ Patients can view real-time battery life and charging status updates via the mobile app for iPhone®



*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 25, 2023, available at www.abbottinvestor.com.

**Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

^ Smallest size determined by volume in cubic centimeters.

1. On a GAAP basis, full-year 2022 Abbott sales increased 1.3%. 2. Full-year 2022 GAAP diluted EPS was \$3.91. 3. Fourth-quarter GAAP diluted EPS was \$0.59. 4. Abbott projected full-year 2022 diluted EPS on a GAAP basis of \$3.75 to \$3.81. 5. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of \$3.05 to \$3.25. Abbott forecasts specified items for the full-year 2023 of \$1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$4.30 to \$4.50 for the full-year 2023. 6. Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151), 2022.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.